<DOC>
	<DOCNO>NCT01788189</DOCNO>
	<brief_summary>Multicenter prospective open-label non-randomised phase I/II study patient relapse refractory CD20-positive aggressive lymphoma Phase I : Dose escalation methotrexate cytarabine ( day 1 , 8 15 28-day cycle ) 3 + 3 design fix dos lenalidomide ( day 1 - 21 ) rituximab ( day 1 ) , maximum 6 cycle Phase II : Treatment 20 patient maximum tolerated dos phase I</brief_summary>
	<brief_title>Lenalidomide , MTX , Ara-C Rituximab Relapsed Aggressive B-cell Lymphomas</brief_title>
	<detailed_description>Phase I The goal phase I part study determine maximum tolerated dos methotrexate cytarabine able combine once-per-cycle rituximab full-dose 3-weeks-on/1-week-off lenalidomide 28-day treatment cycle . Methotrexate cytarabine give three time per cycle , preferably day 1 , 8 15 . If short-term toxicity preclude once-per-week dosing , treatment may delay maximum 3 day , e.g . second injection methotrexate cytarabine may delay day 11 third injection day 21 . The dos methotrexate cytarabine adjust permit administration three dos per cycle without need postpone subsequent treatment cycle 7 day . Dose limit toxicity determine increase dos methotrexate cytarabine sequential patient cohort 3 + 3 design . Because tolerance lenalidomide cytotoxic agent likely decrease increase number treatment cycle , evaluation dose-limiting toxicity confine first two cycle . The requirement dose reduction subsequent treatment cycle rat dose-limiting toxicity . If dose-limiting toxicity observe 3 patient treat dose level , next 3 patient treat next high dose level . If single patient experience dose-limiting toxicity , another 3 patient treat dose level . If one dose-limiting toxicity observe 6 patient treated level , next 3 patient treated subsequent dose level . If two 3 - 6 patient treated level experience dose-limiting toxicity , dose escalation stop . The dose level level dose-limiting toxicity observe defines maximum tolerated dose . The dose level level dose-limiting toxicity observe defines maximum tolerated dos methotrexate cytarabine . However , , lenalidomide dose 25 mg , methotrexate cytarabine escalate beyond first dose level , lenalidomide dose reduce 20 mg , methotrexate/cytarabine dose level produce dose-limiting toxicity repeat lenalidomide dose 20 mg . If , lenalidomide dose 20 mg , methotrexate cytarabine escalate beyond first dose level , lenalidomide dose reduce 15 mg , methotrexate/cytarabine dose level produce dose-limiting toxicity repeat lenalidomide dose 15 mg . If , lenalidomide dose 15 mg , methotrexate cytarabine escalate beyond first dose level , dose limit toxicity reach maximum tolerated dose high dose lenalidomide able combine first dose level methotrexate cytarabine 3 + 3 phase I design . The toxicity profile methotrexate ( mucositis , hepatotoxicity ) cytarabine ( hematotoxicity , hepatotoxicity ) differ . In order determine maximum tolerate dose compound , dose escalation one drug may require maximum tolerate dose methotrexate/cytarabine combination ( define dose level 1 - 5 , see ) determine . If dose-limiting hematotoxicity occur without concomitant dose-limiting mucositis hepatotoxicity , dose methotrexate may escalate without concomitant increase cytarabine dose . Conversely , severe mucositis occur without concomitant dose-limiting hematotoxicity hepatotoxicity , dose cytarabine may escalate without concomitant increase methotrexate dose . Dose modification individual drug make coordinate principal investigator accord observed toxicity use level define methotrexate/cytarabine combination . Toxicities observe first two treatment cycle report trial office within 7 day occurrence ( case serious adverse event within 24 hour ) . Based predefined criterion list coordinate principal investigator trial coordinator decide whether toxicity fulfils requirement dose-limiting toxicity . After inclusion 6 patient dose level coordinate principal investigator trial coordinator decide accord principle outline protocol whether safe move next dose level . If rating toxicity dose-limiting equivocal and/or agreement obtain coordinate principal investigator trial coordinator , principal investigator participate trial site include decision making process . Stepping-up next dose level require vote favor dose escalation . Dose-limiting toxicity : - follow day methotrexate/cytarabine injection ( day 8 + ≤ 3 day / day 15 + ≤ 6 day first second treatment cycle ; day 1 second third cycle equivalent day 29 + ≤ 7 day previous cycle ) : neutrophil &lt; 500/µl , platelet &lt; 25.000/µl , creatinine clearance &lt; 60 ml/min , bilirubin ≥ 3,0 mg/dl , serum AST/GOT ALT/GPT ≥ 6 x upper limit normal , mucositis grade 3 4 - requirement dose reduction methotrexate/cytarabine first second treatment cycle - few 21 day lenalidomide first second treatment cycle - toxicity-related delay second third treatment cycle 7 day - toxicity prevent continuation therapy accord protocol first second treatment cycle ( except allergic reaction ) Depending previous treatment history patient vary tolerance LeMLAR regimen . To provide maximum therapeutic benefit , dose methotrexate cytarabine escalate within individual patient cycle 2 4 detail provide dose limit toxicity occur previous treatment cycle . Dose escalation cycle 3 6 individual patient use determine dose-limiting toxicity . This do cycle 1 2 . Patients receive 6 treatment cycle unless tumor progression , unacceptable toxicity treatment intolerance occur . Treatment intolerance include physician patient preference discontinue change treatment manner compatible protocol . If treatment accord LeMLAR protocol prematurely stop , result must document procedure outline protocol . Definition dose level methotrexate cytarabine ( cohorts 3 - 6 patient ) : Level 1 Cycles 1 - 2 : methotrexate 30 mg/m² , cytarabine 75 mg/m² ; cycle 3 - 4 : dose-limiting toxicity occur cycle 1 2 : methotrexate 60 mg/m² , cytarabine 150 mg/m² ; cycle 5 - 6 : dose-limiting toxicity occur cycle 3 4 : methotrexate 90 mg/m² , cytarabine 225 mg/m² Level 2 Cycles 1 - 2 : methotrexate 60 mg/m² , cytarabine 150 mg/m² ; cycle 3 - 4 : dose-limiting toxicity occur cycle 1 2 : methotrexate 90 mg/m² , cytarabine 225 mg/m² ; cycle 5 - 6 : dose-limiting toxicity occur cycle 3 4 : methotrexate 120 mg/m² , cytarabine 300 mg/m² Level 3 Cycles 1 - 2 : methotrexate 90 mg/m² , cytarabine 225 mg/m² ; cycle 3 - 4 : dose-limiting toxicity occur cycle 1 2 : methotrexate 120 mg/m² , cytarabine 300 mg/m² ; cycle 5 - 6 : dose-limiting toxicity occur cycle 3 4 : methotrexate 150 mg/m² , cytarabine 375 mg/m² Level 4 Cycles 1 - 2 : methotrexate 120 mg/m² , cytarabine 300 mg/m² ; cycle 3 - 6 : dose-limiting toxicity occur cycle 1 2 : methotrexate 150 mg/m² , cytarabine 375 mg/m² Level 5 Cycles 1 - 6 : methotrexate 150 mg/m² , cytarabine 375 mg/m² Phase II The result phase I part trial summarize submit interim report Celgene . Initiation phase II require reliable data define maximum tolerate dose demonstration clinical activity least patient treated phase I . A total 20 evaluable patient treat maximum tolerated dose level . If phase I three patient treat maximum tolerated dose , another 15 add phase II . If six patient treated phase I , another 12 include phase II . Patients phase II part receive maximum 6 treatment cycle . If dose-limiting toxicity occur first two cycle , dos methotrexate cytarabine may escalate cycle 3 4 , , case toxicity cycle 3 4 , cycle 5 6 . Treatment stop prematurely case tumor progression , unacceptable toxicity , intolerance physician patient preference .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Age ≥ 18 year Performance status ECOG 0 3 First subsequent relapse refractoriness biopsyproven CD20positive aggressive B cell lymphoma ( exclude mantle cell lymphoma ) Measurable disease Ineligibility unwillingness undergo highdose chemotherapy autologous stem cell transplantation Ability understand aim study act accordingly Effective contraception Signed informed consent Central nervous system relapse aggressive lymphoma Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study Any condition include presence laboratory abnormality place subject unacceptable risk he/she participate study Any condition confounds ability interpret data study Inadequate organ function related aggressive lymphoma : neutrophil &lt; 1.0/nl platelet &lt; 75/nl creatinine clearance &lt; 60 ml/min bilirubin ≥ 2,5 mg/dl serum AST/GOT ALT/GPT ≥ 4 x upper limit normal Active viral hepatitis ( HBV , HCV ) , HIV infection , uncontrolled infection Pregnancy nursing period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>CD20</keyword>
	<keyword>Relapse</keyword>
	<keyword>Lenalidomide</keyword>
</DOC>